Welcome to our dedicated page for Virios Therapeutics news (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics stock.
Virios Therapeutics news covers a development-stage biotechnology company focused on antiviral therapies for diseases associated with a virally triggered abnormal immune response, including fibromyalgia and Long-COVID. Company updates have centered on fixed-dose antiviral and celecoxib combinations, including IMC-1, a famciclovir-and-celecoxib candidate with FDA Fast Track designation, and IMC-2, a valacyclovir-and-celecoxib candidate studied in Long-COVID.
Recurring developments include clinical and regulatory updates, quarterly financial results, cash runway commentary, public equity offerings, shareholder voting matters, governance items and capital-structure disclosures tied to VIRI common stock.
Virios Therapeutics has priced its initial public offering (IPO) at $10.00 per share, aiming to raise $30 million through the sale of 3,000,000 shares. The IPO will begin trading on the Nasdaq under the ticker symbol VIRI on December 17, 2020, with an expected closing date of December 21, 2020. The offering includes a 45-day option for underwriters to purchase an additional 450,000 shares. This funding will further the company's development of novel antiviral therapies targeting diseases linked to viral-triggered immune responses.
Virios Therapeutics has priced its initial public offering of 3,000,000 shares at $10.00 each, aiming for $30 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase up to 450,000 additional shares. Trading will commence on December 17, 2020, under ticker symbol 'VIRI', with the offering expected to close on December 21, 2020. The company focuses on developing antiviral therapies for diseases triggered by abnormal immune responses, with its lead candidate, IMC-1, targeting chronic conditions linked to HSV-1.